The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma: A preliminary report

Cancer

Volumn 77, Issue 11, 1996, Pages 2286-2293

  Method, Michael W ^a   Serafini, Aldo N ^a   Averette, Hervy E ^a   Rodriguez, Michael ^a   Penalver, Manuel A ^a   Sevin, Bernd Uwe ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

computed tomography; monoclonal antibodies; ovarian carcinoma; radioimmunoscintigraphy; reassessment laparotomy; second look laparotomy

Indexed keywords

ANTIBODY CONJUGATE; CA 125 ANTIGEN; CISPLATIN; CYTOTOXIC AGENT; INDIUM 111; INDIUM CHLORIDE IN 111; MONOCLONAL ANTIBODY B.72.3; ONCOSCINT CR OV; PACLITAXEL; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOPSY; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOSCINTIGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; LAPAROTOMY; OVARY CARCINOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECOND LOOK SURGERY; SINGLE BLIND PROCEDURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INDIUM RADIOISOTOPES; LAPAROTOMY; MICE; MIDDLE AGED; NEOPLASM, RESIDUAL; OLIGOPEPTIDES; OVARIAN NEOPLASMS; PACLITAXEL; PENTETIC ACID; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOIMMUNODETECTION; REMISSION INDUCTION; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 0029884128     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960601)77:11<2286::AID-CNCR16>3.0.CO;2-T     Document Type: Article

References (30)

1. Hoskins WJ, Rubin SC. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 1991;18(3):213-21.
2. Gershenson DM, Copeland LJ, Wharton JT, Atkinson EN, Sneige N, Edwards CL, et al. Prognosis of surgically determined complete responders in advanced ovarian cancer. Cancer 1985;55:1129-35.
3. Rubin SC, Hoskins WJ, Saigo PE, Chapman D, Hakes TB, Markman M, et al. Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol Oncol 1991;42:137-41.
4. Miller DS, Ballon SC, Teng NNH, Seifer DB, Soriero OM. A critical reassessment of second-look laparotomy in epithelial ovarian carcinoma. Cancer 1986;57:530-5.
5. Ballon SC, Portnuff JC, Sikic BI, Turbow MM, Teng NN, Soriero O. Second-look laparotomy in ovarian cancer: precise definition, sensitivity and specificity of the operative procedure. Gynecol Oncol 1984;17:154-60.
6. Shepherd JH, Granowska M, Britton KE, Mather S, Epenetos AA, Ward BG, et al. Tumor-associated monoclonal antibodies for the diagnosis and assessment of ovarian cancer. Br J Obstet Gynaecol 1987;94:160-7.
7. 2 versus abdominal CT scan in the detection of residual disease in ovarian cancer patients. Int J Cancer 1988;(Suppl)3:83-8.
8. Serafini A. Biocompatible MoAbs detect, stage disease. Diagn Imaging 1990;149:94-8.
9. Massuger L, Kenemans P, Claessens R, Verheijen R, Schijf C, Strijk SP, et al. Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3 F(ab′)2 monoclonal antibody. J Nucl Med 1990;31:1802-10.
10. Krag DN. Antibody imaging for ovarian cancer. Appl Radiol 1992;Vol 21:30-3.
11. 111In-CYT-103 immunoscintigraphy in ovarian cancer. Gynecol Oncol 1993;48:285-92.
12. Chatal J-F, Fumoleau P, Saccavini J-C, Thedrez P, Curtet C, Bianco-Arco A, et al. Immunoscintigraphy of recurrences of gynecologic carcinomas. JNucl Med 1987;28:1807-19.
13. Low RN, Carter WD, Saleh F, Sigeti JS. Ovarian cancer: comparison of findings with perfluorocarbon-enhanced MR imaging, IN-111-CYT-103 immunoscintigraphy, and CT. Radiology 1995;195:391-400.
14. Gallup DG. Multicenter clinical trial of 111-In-CYT-103 in patients with ovarian cancer. In: Maguire RT, van Nostrand D, editors. Diagnosis of colorectal and ovarian carcinoma. Application of immunoscintigraphic technology. New York: Marcel Dekker Inc., 1992:111-24.
15. Hertel A, Baum R. Influence of human anti-murine antibodies on in vitro assays in ovarian cancer patients. Hybridoma 1993;12(5):571-6.
16. SAS User's Guide. Statistics Version 6. Cary, NC: Sas Institute, Inc., 1992.
17. Collier BD, Abdel-Nabi H, Doerr JR, Harwood SJ, Olsen J, Kaplan EH, et al. Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT. Radiology 1992;185:179-86.
18. Wingo PA, Tong T, Bolder S. Cancer statistics: 1995. CA Cancer J Clin 1995;45:8-30.
19. Qazi F, McGuire WP. The treatment of epithelial ovarian cancer. CA Cancer J Clin 1995;45:88-101.
20. Ozols RF, Rubin SC, Dembo AJ, Robboy S. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, editors. Principles and practice of gynecologic oncology. Philadelphia: JB Lippincott, 1992:731-81.
21. Rubin SC, Hoskins WJ, Hakes TB, Markman M, Cain JM, Lewis JL. Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors. Am J Obstet Gynecol 1988;159:1094-8.
22. McGuire WP, Hoskins WJ, Brady MF, Kecera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and Stage IV ovarian cancer. N Engl J Med 1996;334(1):1-6.
23. Ho AG, Beller U, Speyer JL, Colombo N, Wernz J, Beckman EM. A reassessment of the role of second-look laparotomy in advanced ovarian cancer. J Clin Oncol 1987;5:1316-21.
24. Friedman JB, Weiss NS. Sounding board. Second thoughts about second-look laparotomy in advanced ovarian cancer. N Engl J Med 1990;322:1079.
25. Krag DN, Ford P, Smith L, Taylor M, Schneider PD, Bushberg JT, et al. Clinical immunoscintigraphy of recurrent ovarian cancer with indium 111-labeled B72.3 monoclonal antibody. Arch Surg 1993;128:819-23.
26. 111Cyt103 prior to second look laparotomy in ovarian cancer. A pilot study. Am J Clin Oncol 1994;17(4):331-4.
27. Clarke-Pearson DL, Bandy LC, Dudzinski M, Heaston D, Creasman WT. Computed tomography in evaluation of patients with ovarian carcinoma in complete clinical remission: correlation with surgical-pathologic findings. JAMA 1986;255:627-30.
28. Rubin SC, Lewis JL Jr. Second-look surgery in ovarian carcinoma. Crit Rev Oncol Hematol 1988;8(1):75-91.
29. Silverman PM, Osborne M, Dunnick NR, Bandy LC. CT prior to second-look operation in ovarian cancer. Am J Roentgenol 1988;150:829-32.
30. Ngan HYS, Wong LC, Chan SYW, Ma HK. Role of CA125 and abdominal pelvic computerized axial tomogram in monitoring of chemotherapy treatment of ovarian cancer. Cancer Invest 1990;8(5):467-70.